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Mutations of PLA2G6 gene are responsible for PARK14, an autosomal recessive L-DOPA
responsive dystonia/parkinsonism with early/adult onset. This phenotype possesses an
high clinical variability, which consists in the occurrence of cerebral and cerebellar atrophy,
iron accumulation in the basal ganglia, and cognitive decline. This report describes a
PD patient carrying an heterozygous PLA2G6 mutation, which was identified also in
his PD affected sister. This patient is characterized by a L-DOPA responsive typical
parkinsonian syndrome without the occurrence of dystonia, a slight cognitive decline,
presence of iron accumulation both in neo and paleostriatum while cerebellar atrophy
was absent. Clinical and imaging features are compatible with the PARK14 phenotype.
Although PARK14 has been previously reported to be inherited as a recessive disorder,
clinical and genetic analysis of this proband and his family rise the hypothesis that even
heterozygous PLA2G6 mutations may cause PARK14. It remains to be analyzed whether
these heterozygous variants may act as dominant mutations, or they merely increase the
risk to develop PD by acting within a context of synergistic genetic and/or environmental
backgrounds.
Keywords: genetic of Parkinson’s disease, incomplete penetrance, PARK14, Parkinson and iron accumulation,
L-DOPA responsive
BACKGROUND
Phospholipase A2-associated neurodegeneration (PLAN), a syndrome of Neurodegeneration with
Brain Iron Accumulation (NBIA), is an autosomal recessive neurological disorder caused by
mutations in the PLA2G6 gene (1).
PLAN syndrome encompasses a group of phenotypes like classic infantile neuroaxonal
dystrophy (INAD), and atypical neuroaxonal dystrophy of childhood-onset (atypical NAD),
characterized by high levels of iron, especially in the globus pallidus (2, 3).
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PLA2G6 gene encodes a calcium-independent group VI
phospholipase A2 (iPLA-VI), which is critical in regulating cell
membrane homeostasis, mitochondrial function and membrane
remodeling (4, 5). Moreover, elevated expression of α-Synuclein
(α-Syn) in neuronal mitochondria occurs constantly in PLA2G6-
deficiency (6).
Because of its role in the generation of reactive oxygen species
and its association with neurodegeneration with brain iron
accumulation, an involvement of PLA2G6 in the pathogenesis of
Parkinson’s disease (PD) was proposed. In fact, oxidative stress
and increased brain iron deposits play a pivotal role in the genesis
of PD (7).
In line with this, in 2008 PLA2G6 gene was shown to be
the causative gene underlying PARK14, an autosomal recessive
L-DOPA responsive dystonia/parkinsonism with early or adult-
onset (8–12). These patients suffer from dystonia, bradykinesia,
rigidity, and marked cognitive decline. Subsequently, a range
of phenotypes has been reported, from pure Parkinsonism to
severe generalized dystonia. While brain MRI shows cerebellar
atrophy in almost all well-established PLAN cases, in adult-
onset PARK14 little cerebellar atrophy is observed (13–
19).
To date, there are about 80 different PLA2G6 gene
abnormalities, and no mutation hot spots have been reported
so far. PLA2G6 genotype-phenotype correlation is described
in INAD patients with homozygous null mutations, and in
some PARK14 patients, where truncated mutations produce a
complex phenotype with cortical and cerebellar atrophy (8, 20–
25).
Autosomal recessive inheritance of PARK14 suggests
that PLA2G6 mutations cause the loss of PLA2G6 function
and impair the ability of PLA2G6 to protect mitochondria
against apoptotic stimuli and exert a neuroprotective effect on
dopaminergic cells (4).
In this manuscript, we describe a patient carrying a
PLA2G6 mutation which is affected by familial PD, with
some clinical and imaging features which are compatible with
the PARK14 phenotype. Unexpectedly, this patient carries
an heterozygous mutation in the PLA2G6 gene, despite the
evidence provided so far indicates the occurrence of PD
only in homozygosis. Strengthening this unique genotype-
phenotype correlation, PD was present also in the sister
of the proband, who is also a carrier of the heterozygous
mutation. Remarkably, in non-carrier sibling PD was not
present.
CLINICAL PRESENTATION
The proband, a 69 years old caucasian man (II:7), was diagnosed
with familial PD at the age of 55. Both parents (I:1 and I:2, died,
respectively at 85 and 91) and two siblings (II:3, 72 years old and
II:6, 71 years old) did not show any neurological sign so far. In
contrast, his 74 years old sister (II:2) was recently diagnosed with
PD at the age 67 (Figure 1A).
In the medical history of the proband (II:7), no
noticeable acute or chronic disorders potentially related
to parkinsonism has been reported. In 2004, he presented
rigidity of upper and lower left limbs, freezing of gait, and
non-motor symptoms (urinary incontinence and reduced
olfaction). He was responsive to L-DOPA+benserazide
250+25, which led the UPDRS III score from 17 to 9
during the on- and off-phase respectively. Brain MRI
(1,5 Tesla, GE Healthcare), spinal MRI, ECG and evoked
potentials were normal at the time of PD diagnosis. The
electromyogram (EMG) showed a slight denervation at perineal
level.
Three years later a DAT-Scan was carried out, suggesting
a marked asymmetric reduction of dopamine (DA) uptake
sites within the right basal ganglia (Figure 2A). Five years
later, in 2012, DAT-Scan consistently indicated nigro-striatal
denervation. Neuropsychological assessment (MMSE) was
reported within the normal range.
In 2014 brain MRI showed enlargement of sub-aracnoid
spaces bilaterally, surrounding frontal lobes. ECG reported
abnormal heart rate recovery. The UPDRS-III registered a
deterioration (off = 42, on = 12), and electroneurography was
consistent with mild axonal sensory polyneuropathy. There was
still no cognitive deterioration at MMSE, while neither mood nor
obsessive disorders were reported.
In 2017, the UPDRS-III in the on phase was 20 and
a gait disturbance appeared along with involuntary oro-
facial dyskinesia. Brain MRI revealed post-central atrophy
and bilateral temporo-insular atrophy (Figure 2B-I), along
with a reduced thickness of the mesencephalic tegmentum
(Figure 2B-II). There was no cerebellar atrophy, while in
the basal ganglia brain iron accumulation was remarkable
involving the head of the caudate nucleus, putamen and
globus pallidus (Figure 2B-III). Spinal MRI, electrocardiogram,
electromyogram and electroneuronography were unchanged
compared with 2014. At this time a slight cognitive deterioration
appeared (MMSE 23/30).
A written informed consent for genetic analysis was
obtained, and clinical exome sequencing considered 4800
human genes including 17 genes related to Parkinson disease
(PARK1:SNCA; PARK2:PRKN; PARK3:SPR; PARK5:UCHL1;
PARK6:PINK1; PARK7:DJ1; PARK8: LRRK2; PARK9:ATP13A2;
PARK10:ELAVL4; PARK11:GIGYF2; PARK12:TAF1;
PARK13:HTRA2; PARK14:PLA2G6; PARK15:FBXO7;
PARK16:ADORA1; PARK17:VPS35; PARK18:EIF4GI) (TruSight
One Sequencing Panels, Illumina) was performed. Sequence
analysis identified the mutation p.Asp31Asn (NP_003551.2),
c.91G>A (NM_003560.2:) (rs150024227) in PLA2G6 gene
(OMIM #603604), confirmed by Sanger sequencing (Figure 1B).
No mutations in other PD-related genes were identified.
Multiple-ligation probe amplification (MLPA) (SALSAMLPA kit
P120-B2, MRC-Holland) ruled out the presence of duplication
or deletion as second mutation (Figure 1C). After a genetic
counseling, the presence of p.Asp31Asn was evaluated in II:2
(PD affected sister just diagnosed) and II:6 (healthy sister). The
same p.Asp31Asn variant was confirmed in II:2, while it was not
present in asymptomatic II:6. Unfortunately, it was impossible
to evaluate this variant in the parents (I:1 and I:2) and in one
healthy brother (II:3).
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FIGURE 1 | Genetic evaluation. (A) Pedigrees of the investigated kindred. Proband (II:7), his affected sister (II:2) and healthy sibling (II:6) are indicated with an arrow;
(B) mutation analysis of p.Asp31Asn (NP_003551.2), c.91G > A (NM_003560.2:) (rs150024227) in exon 2 of PLA2G6 gene (OMIM #603604). Sequence analysis is
shown for proband (II:7), his affected sister (II:2), and healthy sibling (II:6); (C) MLPA analysis of PLA2G6 gene shows the results for proband (II:7), his affected sister
(II:2) and healthy sibling (II:6).
DISCUSSION
This manuscript describes a patient with familial PD, who
carries a p.Asp31Asn variant in PLA2G6, the causative gene of
PARK14. This PD phenotype is characterized by parkinsonism
with dystonia. Clinical variability consists in the occurrence of
cerebral and cerebellar atrophy, iron accumulation in the basal
ganglia, age at onset and cognitive decline.
This patient is characterized by a L-DOPA responsive typical
parkinsonian syndrome without the occurrence of dystonia even
at 15 years after PD diagnosis. At longer time interval, a slight
cognitive decline appeared. MRI showed the presence of iron
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FIGURE 2 | DaTSCAN and Magnetic Resonance Imaging (1,5 Tesla). (A) DATSCAN image showing a reduced tracer uptake in both striatal regions; (B) magnetic
resonance imaging. (I) T2 FLAIR shows post-central atrophy and bilateral temporo-insular atrophy; (II) SWAN shows a reduced thickness of the mesencephalic
tagmen; (III) T1 FSPGR shows signs of iron deposition in the globus pallidum and in both putamen.
accumulation both in neo and paleostriatum while cerebellar
atrophy was absent. No data about disease progression are
available so far for the newly diagnosed sister (II:2) who had a
delayed disease onset compared with the patient reported (67 and
55, respectively).
PARK14 was been described as a recessive disease, where
two mutations (homozygous or compound heterozygous) in
PLA2G6 gene were always present. The patient described here is
uniques since he carries a single mutation affecting the PLA2G6.
This variant segregated with PD in II:2 (PD affected sister just
diagnosed), while it was not present II:6 (healthy sister).
These findings pose the question about the role of
heterozygosity in genes related with PARK 14 and, in general,
autosomal recessive parkinsonism. In fact, specific allelic
variants in the PARK14 locus may lead to PD with an autosomal
dominant inheritance (being still unknown the penetrance). In
keeping with this, a recent report describes an heterozygous
mutation in PARK14 causing PD in a 69 years old patient (23).
This patient was reported to carry all typical features of L-DOPA
responsive PD associated with dystonia, but no evidence of iron
deposition. It could be speculated that only a few mutations
in PLP2G6 could act as dominant, producing a specific kind
of parkinsonism as witnessed by the phenotype described
here compared with other PARK14 patients with two PLA2G6
variants. Further analysis are required to firmly establish whether
specific heterozygous mutations of PARK14 may lead to PD.
Another potential explanation is that heterozygote mutations
in genes related with autosomal recessive parkinsonism lead
to increased risk of PD. In these scenario, the present data
contribute to the working hypothesis that PLA2G6 heterozygote
mutations may represent a risk factor for PD, as reported
for some PLA2G6 mutations in idiopathic PD patients (25).
This is supported by the frequency of this variant in different
populations (ExAC database: minor allele frequency = 0.0004),
and by the presence of single variants reported in sporadic
PD (14). It is fascinating that recent studies report PLA2G6
immunostaining in the core of brainstem-type Lewy bodies from
PARK14 PD patients and, most remarkably, in idiopathic PD (26,
27). This witnesses for a role of PLA2G6 in the physiopathology
of PD thus remarking the potential role of environmental
interactions as well as genetic background.
However, it is still debated whether heterozygous carriers
of mutations of genes related with autosomal recessive
parkinsonism own an increased risk to develop PD (28).
Although more than 50% of patients with mutations in parkin
or PINK1 have only a single heterozygous mutation, the few
large studies that assessed the frequency of heterozygotes remain
controversial (29, 30). In fact, while a retrospective analysis
of the occurrence of PINK1 heterozygous rare variants in PD
could not detect significant differences compared with controls,
another study reported that heterozygous CNVs (Copy Number
Variations) in PARK2 gene could confer an higher risk to develop
PD (28, 30).
Therefore, although the pathogenic significance of these
variants remains uncertain, they may represent a risk factor to
develop PD, supporting the hypothesis that haplo-insufficiency
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is a more likely explanation than compound heterozygosity
through unidentified recessive mutations.
CONCLUSIONS
In this manuscript, we describe a patient carrying a PLA2G6
mutation which is affected by familial PD, with some clinical
and imaging features which are compatible with the PARK14
phenotype. This patient is characterized by a L-DOPA responsive
typical parkinsonian syndrome without the occurrence
of dystonia, a slight cognitive decline, presence of iron
accumulation both in neo and paleostriatum while cerebellar
atrophy was absent.
Although PARK14 has been reported so far as a recessive
disease, clinical and genetic analysis of the proband and his
family rise the hypothesis of a potential role of some heterozygous
PLA2G6mutations in causing PARK14. It remains to be analyzed
in detail whether these variants act really as dominant PD-
inducing mutations, or they play a role as risk factors acting
within synergistic genetic and/or environment backgrounds.
Deciphering the role of heterozygosity in parkinsonism is
important for the development of guidelines, for genetic
testing and counseling, and for the understanding of late-onset
Parkinson’s disease.
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